Iulia Iatan

Iulia Iatan

Auto-generated profile, based on publicly available information

Iulia Iatan

Research Institute of the McGill University Health Centre, Montreal, Canada (Erzingatzian, Ruel, Brown, Genest, and Iatan)

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2008 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
IIIulia Iatan
Iulia Iatan
Khalid Al-RasadiKhalid Al-Rasadi
Khalid Al-Rasadi
IRIsabelle Ruel
Isabelle Ruel
KWKhalid Al Waili
Khalid Al Waili
JGJacques Genest
Jacques Genest

25 April 2012 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
IIIulia Iatan
Iulia Iatan
APAurélien Palmyre
Aurélien Palmyre
SASarah Alrasheed
Sarah Alrasheed
IRIsabelle Ruel
Isabelle Ruel
JGJacques Genest
Jacques Genest

24 May 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
IIIulia Iatan
Iulia Iatan
TLTodd C Lee
Todd C Lee
EMEmily G McDonald
Emily G McDonald
Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug widely used as a first-line treatment of hepatitis B virus (HBV) and HIV. Increasing evidence has emerged associating its use with the development of Fanconi syndrome, renal insufficiency and bone disease. We report a case of a 61-year-old woman with a remote history of liver transplant for cirrhosis due to HBV. Over 1 year, the patient had recurrent falls, generalised myalgias and arthralgias, misdiagnosed as fibromyalgia. We discuss a complication of her transplant treatment regimen with the drug TDF leading to a rare but reversible disorder: tenofovir-induced Fanconi osteomalacia with renal phosphate wasting. Though recognised, this rare disorder was initially likely missed due to clinical unfamiliarity with the diagnosis, concomitant psychiatric symptoms and premature diagnostic closure.

19 November 2026 in Atherosclerosis
Verified
Journal Article
Open access
AEArmen Erzingatzian
Armen Erzingatzian
LBLeslie Brown
Leslie Brown
LHLindsay Hales
Lindsay Hales
IRIsabelle Ruel
Isabelle Ruel
GTGeorge Thanassoulis
George Thanassoulis
IIIulia Iatan
Iulia Iatan

15 September 2026 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
IIIulia Iatan
Iulia Iatan
JGJacques Genest
Jacques Genest
Familial hypercholesterolemia (FH) is a semi-dominant, autosomal, monogenic lipoprotein disorder characterized by severe elevations in low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease (ASCVD). The most common form, heterozygous FH, has an estimated prevalence of approximately 1 per 311 individuals, making it one of the most common hereditary disorders in medicine. FH is caused by pathogenic variants in the LDL receptor (LDLR) gene, or in genes encoding proteins involved in receptor-mediated LDL particle uptake, including apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9). Other genes account for a minority of cases.Diagnosis is based on LDL-C levels, a family history of elevated LDL-C or premature ASCVD, supportive physical findings such as tendinous xanthomas, and, when available, molecular confirmation of a pathogenic FH-causing variant. Prompt recognition and treatment with statins, often combined with ezetimibe, modifies the natural course of the disease. Sex differences in FH diagnosis and treatment are widely reported, with women diagnosed later and treated less intensively than men. PCSK9 inhibitors are often required in patients with FH who meet criteria for treatment intensification. In statin-intolerant patients, bempedoic acid may provide additional therapeutic options. The most severe form, homozygous FH (HoFH), has an estimated prevalence of ~1 in 367,000 individuals and is associated with ASCVD in youth, calcific aortic stenosis, and a markedly reduced life expectancy. Patients with HoFH require specialized care and may need LDL apheresis and specific orphan drugs such as lomitapide or evinacumab.

2 September 2026 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
MPMartine Paquette
Martine Paquette
AEArmen Erzingatzian
Armen Erzingatzian
IRIsabelle Ruel
Isabelle Ruel
ZAZobaida Al-Baldawi
Zobaida Al-Baldawi
LBLeslie Brown
Leslie Brown
ABAlexis Baass
Alexis Baass